{"id":25878,"date":"2025-12-17T09:24:48","date_gmt":"2025-12-17T08:24:48","guid":{"rendered":"https:\/\/www.izb-online.de\/?p=25878"},"modified":"2025-12-18T10:36:36","modified_gmt":"2025-12-18T09:36:36","slug":"t-curx-secures-20m-series-a-to-advance-non-viral-car-t-platform","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/t-curx-secures-20m-series-a-to-advance-non-viral-car-t-platform\/","title":{"rendered":"T-CURX announces $20M Series A first closing led by BiomedVC to fund pipeline of clinical-stage CAR-T programs and advance proprietary non-viral in vivo CAR-T platform"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text css=”” el_class=”gco-magazine–title”]<\/p>\n

T-CURX announces $20M Series A first closing led by BiomedVC to fund pipeline of clinical-stage CAR-T programs and advance proprietary non-viral in vivo CAR-T platform<\/h1>\n

[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine-lead”]Financing supports clinical development of non-viral CAR-T therapies in AML and solid tumors and advances a scalable in vivo CAR-T generation platform.[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine–post-date”]December, 2025[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns” el_id=”corona-ausblenden”][vc_column_inner el_class=”bild-zwei-spalten-links”][vc_single_image image=”6283″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Pieris[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]The Lungs[\/vc_column_text][vc_single_image image=”6285″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Pieris[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Stephen S. Yoder<\/strong>, CEO, Pieris Pharmaceuticals Inc.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”25881″ img_size=”full” css=””][vc_column_text css=”” el_class=”gco-magazine-copyright”]\u00a9 iStock \/ Avosb[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine-picture-discription”]T-CURX announces $20M Series A first closing led by BiomedVC[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text css=””]<\/p>\n

\u201cWe are very much looking forward to support T-CURX to achieve all of their therapeutic and commercial ambitions.\u201d<\/h6>\n

Aristotelis Nastos, Managing Partner and investment director at lead-investor BiomedVC<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text css=””]IZB-based start-up T-CURX GmbH (T-CURX) announced on December 17, 2025, the first closing of a $ 20M (\u20ac 17.7M) Series A financing with a syndicate of European and Asian investors for accelerating clinical development of T-CURX non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as advancing T-CURX proprietary non-viral technologies for in vivo CAR-T generation.<\/p>\n

The Series A syndicate was led by BiomedVC and included Bayern Kapital, HighLight Capital (HLC), and i&iBio Fund, as additional investors along with existing and new individual investors.<\/p>\n

Ulf Grawunder, PhD, co-founder and CEO of T-CURX, commented on the closing of this Series A financing round for T-CURX:\u201cI am very excited that T-CURX attracted such a high-profile, international investor\u2019s syndicate, led by BiomedVC, for financing T-CURX`s non-clinical and clinical CAR-T technologies and CAR-T pipeline programs, respectively. It is a testament of the high quality of T-CURX data and the promise of our non-clinical and clinical non-viral CAR-T pipeline in AML & CLL and solid tumor indications going after novel targets. It also highlights the high value of our unique approach to leverage non-viral CAR-vector and LNP technologies for highly economical and scalable in vivo CAR-T generation, in order to \u201cdemocratize\u201d CAR-T therapies for patients globally.\u201d<\/p>\n

Aristotelis Nastos, PhD, Managing Partner and investment director at lead-investor BiomedVC adds:
\n\u201cI am thrilled about leading a highly dedicated international syndicate of early-stage investors from Europe and Asia in this Series A financing for T-CURX. We were deeply impressed by the data on non-viral CAR-T product and technology development at T-CURX, the track-record and experience of T-CURX Founder\u2019s and Management team and the promise of T-CURX non-viral CAR-T technolgies hold for making CAR-T therapies accessible and affordable for many cancer patients globally. We are very much looking forward to support T-CURX to achieve all of their therapeutic and commercial ambitions\u201d<\/p>\n

T-CURX<\/strong> is a German Biotech company located in W\u00fcrzburg and Munich, Germany, spun-out of the laboratory of its co-founder, Prof. Michael Hudecek, University of W\u00fcrzburg, who is a European KOL and pioneer in the development and clinical translation of non-viral CAR-T cell therapies to target various types of cancer<\/strong>.<\/p>\n

About T-CURX<\/strong>
\nT-CURX is a privately owned, German Biotech company based in W\u00fcrzburg founded in 2017 with the vision of bringing next-generation CAR-T cell therapies manufactured with cost-effective and highly scalable non-viral CAR-T cell technologies to more cancer patients in need of more effective cancer therapies. T-CURX was spun out of the laboratory of T-CURX co-founder Prof. Michael Hudecek at the University of W\u00fcrzburg and is led by Ulf Grawunder, PhD, a seasoned serial entrepreneur as CEO, who is also one of the co-founders. T-CURX leverages a portfolio of proprietary non-viral CAR-T technologies for scalable and cost-effective CAR-T manufacturing based on virus-free, Sleeping-beauty transposon gene transfer into patient\u2019s T cells. For more information about T-CURX visit the web-site www.t-curx.com<\/a><\/p>\n

About BiomedVC <\/strong>
\nBiomedVC is is a leading Swiss early-stage VC at the center of European biotech. BiomedVC builds companies around the most intriguing innovation. We strive to enable founders and their ideas. We work together on a basis of equality – as a team and with entrepreneurs. We focus on scientific excellence, building strong companies to create medical and commercial value and bring new medicines to market that improve patient\u2019s lives.<\/p>\n

For further information:<\/strong>
\nUlf Grawunder, CEO
\nE-mail: ulf@t-curx.com<\/a><\/p>\n

For media enquiries:<\/strong>
\nPhone: +49-(0)-931-250-99-712
\nE-mail: pr@t-curx.com<\/a>[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n